The safety and efficacy of anti-CD20 therapy (rituximab) in systemic sclerosis

Completed

• Conditions: Systemic sclerosis; Musculoskeletal Diseases

• Registration Number: ISRCTN77554566
• Lead Sponsor: Catholic University of the Sacred Heart (Italy)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07-30
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Systemic sclerosis patients aged 18 - 70 years , either sex
2. Diffuse cutaneous involvement
3. A worsening of skin score higher than 10% despite conventional therapies

Exclusion Criteria

Severe pulmonary and cardiac involvement

Study & Design

• Study Type: Interventional
• Study Design: Not specified